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LNMC resulted in expansion of polyclonal HPV-specific 
T cells in all patients. On average a 36-fold expansion of 
a CD4+ and/or CD8+ HPV16-specific T cell population 
was observed, which maintained its capacity for second-
ary expansion. The T helper type 1 cytokine IFNγ was 
produced in all cell cultures and in some cases also the 
Th2 cytokines IL-10 and IL-5. The procedure was highly 
reproducible, as evidenced by complete repeats of the 
stimulation procedures under research and under full good 
manufacturing practice conditions. In conclusion, TDLN 
represent a rich source of polyclonal HPV16 E6- and 
E7-specific T cells, which can be expanded under clinical 
grade conditions for adoptive immunotherapy in patients 
with cervical cancer.
Keywords Human papillomavirus · Tumor-draining lymph 
node · Cervical cancer · Adoptive cell transfer ·  
HPV-specific T cells · Good manufacturing practice
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Introduction
Cancer of the cervix uteri is the fourth most common can-
cer among women worldwide, with over 500,000 new 
cases and 200,000 deaths each year [1]. It is induced by 
Abstract Adoptive transfer of tumor-specific T cells, 
expanded from tumor-infiltrating lymphocytes or from 
peripheral blood, is a promising immunotherapeutic 
approach for the treatment of cancer. Here, we stud-
ied whether the tumor-draining lymph nodes (TDLN) of 
patients with human papillomavirus (HPV)-induced cervi-
cal cancer can be used as a source for ACT. The objectives 
were to isolate lymph node mononuclear cells (LNMC) 
from TDLN and optimally expand HPV-specific CD4+ 
and CD8+ T cells under clinical grade conditions. TDLN 
were isolated from 11 patients with early-stage cervical 
cancer during radical surgery. Isolated lymphocytes were 
expanded in the presence of HPV16 E6 and E7 clinical 
grade synthetic long peptides and IL-2 for 22 days and 
then analyzed for HPV16 specificity by proliferation assay, 
multiparameter flow cytometry and cytokine analysis as 
well as for CD25 and FoxP3 expression. Stimulation of 
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persistent infection with oncogenic types of HPV, of which 
high-risk type 16 accounts for over 50 % of the cases [2]. 
Whereas early-stage cervical cancer displays a low recur-
rence risk after treatment (15 %), this is up to 70 % for 
more advanced stages [3–6]. Metastatic cervical cancer is 
prototypically chemotherapy resistant and requires better 
treatments.
Adoptive transfer of tumor-specific T cells is a promis-
ing immunotherapeutic treatment modality for patients 
with advanced or recurrent cancer. Infusions of ex vivo 
expanded TILs resulted in tumor regressions of lymphoma, 
Hodgkin’s disease and melanoma [7–9]. Good clini-
cal responses following ACT are related to recognition of 
tumor-specific antigens [10, 11] by both CD4+ and CD8+ 
T cells. Since (metastatic) cervical cancer cells express the 
viral E6 and E7 oncoproteins, these are good tumor-spe-
cific antigens to be targeted by ACT. Indeed, strong spon-
taneous and vaccine-induced T cell responses to HPV16 
E6 and E7 are protective and able to induce regression of 
premalignant lesions [12–14], whereas ACT with TIL con-
taining HPV-specific T cells of metastatic cervical cancer 
patients resulted in an objective clinical response in three 
of the nine treated patients [15].
Our studies on the systemic and local HPV16-specific T 
cell response in cervical cancer patients revealed that these 
responses are detectable in only 30 % of the blood [16] 
and 35 % of the tumor specimens [17] of these patients, 
indicating that blood or tumor tissue may not function as 
a consistent source for HPV-specific T cells. However, the 
TDLN of patients with cervical cancer more frequently 
(50–83 %) contain HPV-specific T cells [17, 18] reactive to 
many epitopes [18], suggesting that TDLN may form bet-
ter starting material to obtain cells for ACT. To investigate 
this, we expanded and characterized HPV-specific CD4+ 
and CD8+ T cells from lymph node mononuclear cells 
(LNMC) in patients with HPV16-induced cervical can-
cer under clinical grade (i.e., GMP) conditions and found 
that this reproducibly led to the expansion of polyclonal 
HPV16-specific type 1 T cell populations.
Materials and methods
Subjects
Eleven women with histologically proven early-stage 
HPV16-positive cervical cancer enrolled in the CIR-
CLE study, which investigates cellular immunity against 
HPV16+ anogenital lesions, were analyzed for the pres-
ence of HPV16+-specific T cells in their TDLN. HPV sta-
tus was tested using HPV16-specific primers on DNA iso-
lated from surgical resection specimens [19]. The patients 
were staged according to International Federation of 
Gynecology and Obstetrics (FIGO) and treated by radical 
hysterectomy and bilateral pelvic lymphadenectomy. The 
mean age was 44 years (median 42; range 28–65 years). 
Nine patients were staged FIGO IB1, one patient FIGO IB2 
(C809) and one patient FIGO IIA (C800); all patients had 
squamous cell carcinoma. An additional 8 HPV16+ cervi-
cal cancer patients were incorporated of whom the blood 
samples were analyzed. Six patients were staged FIGO 
IB1, one patient IIA (C417) and one patient IA1 (C436). 
The study design was approved by the Medical Ethi-
cal Committee of the Leiden University Medical Center 
(LUMC), Leiden, The Netherlands.
Isolation of peripheral blood mononuclear cells
Venous blood samples (54 mL) were drawn, and periph-
eral blood mononuclear cells (PBMC) were isolated using 
Ficoll density gradient centrifugation and cryopreserved as 
described earlier [14].
Isolation and stimulation of lymph node‑derived T cells
TDLN, suspected for tumor cell infiltration, were derived 
from the pelvic region and sampled during standard lym-
phadenectomy. The lymph nodes were cut into pieces, 
incubated for 1 h with collagenase IV (200 IU/ml, Sigma, 
St Louis, USA) and DNAse (50 mg/ml, Sigma) at 37 °C, 
after which a single cell suspension of the lymph node 
mononuclear cells (LNMC) was made using a cell strainer 
(BD, Erebodemgem, Belgium). LNMC samples were cryo-
preserved in 90 % FCS (Life Technologies, Bleiswijk, The 
Netherlands)/10 % DMSO (WAK-Chemie Medical, Stein-
bach, Germany) using a freezing machine and stored in the 
vapor phase of the liquid nitrogen. Alternatively, the lymph 
node was cut in half, and one side was scraped with a scal-
pel to obtain a layer of single cells of the LNMC, which 
were then cryopreserved. Only in two cases, patient C727 
and patient C796, the resected lymph node used for the 
study was found to be tumor cell negative upon pathologi-
cal examination.
For the test, LNMC were thawed, washed and seeded at 
a density of 0.5–2 × 106 cells per well of a 24-well plate in 
1 ml of IMDM (Lonza, Breda, The Netherlands) enriched 
with 10 % pooled human AB serum (Sanquin Blood-
bank, Dordrecht, The Netherlands), penicillin (100 U/ml), 
streptomycin (100 µg/ml) and 2 mM l-glutamin (all from 
Lonza) and stimulated with HPV16 E6 and E7 clinical 
grade long peptide pools (5 µg/ml) in the presence of either 
recombinant human IL-2 (Aldesleukin, Novartis, Arnhem, 
The Netherlands) at 3 different concentrations (75, 150 and 
300 U/ml) or a combination of 10 % T cell growth factor 
(TCGF; Zeptometric, Buffalo, USA) and 5 ng/ml recom-
binant human IL-15 (PeproTech, Hamburg, Germany), 
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for a total of 22 days. The IL-2 and TCGF/IL-15 were 
added when culture medium was refreshed. Based on the 
results obtained, following LNMC were stimulated with 
GMP-grade materials only (C331, C427, C711-II, C707, 
C726-I and C726-II, and C727-I and C727-II), in which 
150 U/ml IL-2 was added three times a week. In order to 
test the secondary expansion capacity [20, 21], 22-day 
cultured LNMC from C331, C427, C711 and C707 were 
re-stimulated using antigen-loaded autologous monocytes 
for another 3 weeks and then tested for responsiveness by 
proliferation, cytokine production and multiparameter flow 
cytometry. The expansion capacity was expressed as the 
fold change, which is the total number of viable cells at the 
end of the culture period (day 22) divided by the starting 
number of viable cells (both in case of the first and second 
expansion period). The remaining LNMC bulk culture cells 
were cryopreserved in 90 % FCS/10 % DMSO.
Antigens
To stimulate LNMC, clinical grade HPV16 E6 and E7 
long (25–35-mer) overlapping peptides (HPV16 E6: 9 pep-
tides, HPV16 E7: 4 peptides) were synthesized in the GMP 
facility of the LUMC [13, 22]. To analyze the response of 
LNMC, a set of overlapping 22-mer peptides spanning the 
entire HPV16 E6 and E7 amino acid sequence as well as 
recombinant E6 and E7 proteins was synthesized [23]. The 
peptides were dissolved as described earlier [24].
Analysis of T cell specificity and cytokine secretion
Expanded LNMC (50,000 cells/well) were stimulated with 
HPV16 E6 and E7 (22-mer) peptides (5 µg/ml) or protein 
(10 µg/ml)-pulsed autologous APC (i.e., B-LCL or mono-
cytes) in triplicate wells in a 3-day proliferation assay. 
Medium only was taken along as a negative control, and 
PHA (0.5 µg/ml final concentration; HA16, Murex Bio-
Tech, Kent, UK) served as a positive control. After 48 h, 
50 µl supernatant of each of the triplicate wells was pooled 
and stored at −20 °C. During the last 16 h of culture, 50 µl 
of 10 µCi/ml [3H]-thymidine (0.5 µCi/well; PerkinElmer, 
Groningen, The Netherlands) was added to measure pro-
liferation as counts per minute (CPM) [24]. Stimulation 
indexes (SI) above 3, calculated as the average CPM of 
the triple-stimulated cell conditions divided by the average 
CPM of the three control wells consisting of LNMC with 
unloaded APC, were considered to be positive responses.
Antigen-specific production of cytokines in the super-
natants of the proliferation assays was measured by ELISA 
(IFNγ and IL-10, according to the manufacturer San-
quin, Amsterdam, The Netherlands) and/or by the human 
Th1/Th2 cytometric bead array (BD Pharmingen) [14, 23]. 
Antigen-specific cytokine production was defined by a 
cytokine concentration above the cutoff value of the test (as 
defined by the manufacturer) and at least twice the concen-
tration of the medium control (unloaded APC). The phe-
notype and poly-functionality of the T cell reactivity was 
examined by multiparameter flow cytometry as described 
previously [18]. Non-stimulated and PHA-stimulated 
LNMC served as negative and positive control, respectively. 
Responses were considered positive when the percentage 
of HPV-stimulated activated (CD154+ and/or CD137+) T 
cells and/or the percentage of cytokine producing (IL-2 and/
or IFNγ) T cells was at least 3 times the medium control.
Isolation of T cell clones
T cell clones from the TDLN of patient C331 were isolated 
using limited dilution as described earlier [17]. Briefly, 
CD4+ and CD8+ T cells were isolated using Dynabeads 
(Invitrogen, Carlsbad, CA, USA) or magnetic cell sort-
ing (MACS; and detaching beads, Miltenyi Biotec, Ber-
gisch Gladbach, Germany), respectively. Then, the cells 
were plated at 0.3 cells/well in IMDM (with 5 % human 
AB serum, 5 % FCS and 100 U/ml IL-2) and cultured in 
the presence of irradiated and overnight with HPV16 
E6/E7 peptide-loaded autologous B-LCL as well as feeder 
cells (pooled PBMCs). Re-stimulation was done every 10 
(CD8+) or 14 days (CD4+), and fresh medium with IL-2 
was added weekly. The phenotype and TCRVβ usage [18] 
of T cell clones were tested by flow cytometry. Antigen 
specificity was determined by proliferation and cytokine 
production.
Phenotyping of bulk cultures
The LNMC bulk cultures at day 22 were phenotyped by 
using three sets of markers and analyzed by flow cytometry. 
The cultured T cells were screened for the presence of regu-
latory T cells as described previously [23], the memory sub-
types [25] and expression of inhibitory markers [26]. The 
memory set contains CD3-Pacific Blue (Clone UCHT1; 
DAKO), CD4-PE-CF594 (Clone RPA-T4; BD), CD8-APC-
Cy7 (Clone SK1, BD), CD25-Brilliant Violet 605 (Clone 
2A3, BD), CD27-Horizon V500 (Clone M-T271, BD), 
CD28-FITC (Clone CD28.2, BD), CD45RA-PerCP-Cy5.5 
(Clone HI100, Biolegend), CD45RO-PE (Clone UCHL1, 
BD), CD62L-Alexa Fluor 700 (Clone DREG-56, Bioleg-
end), CD95-PE-Cy7 (Clone DX2, Biolegend) and CCR7-
Alexa Fluor 647 (Clone 3D12, BD). The inhibitory set con-
sists of the same antibodies for CD3, CD4 and CD8 and 
additionally CD152-PE-Cy5 (Clone BN13, BD), CD279-
Brilliant Violet 605 (Clone EH12.2H7, Biolegend) and 
TIM3-PE (Clone F38-2E2, Biolegend). The cryopreserved 
bulk LNMC were thawed, and after dead cell staining (yel-
low fixable live/dead staining kit, Invitrogen) for 20 min at 
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room temperature (RT) in the dark, the cells (2 × 106) were 
washed in PBS supplemented with 0.5 % bovine serum 
albumin (BSA), incubated for 10 min at RT in PBS/0.5 % 
BSA/10 %FCS (in the dark) to prevent nonspecific anti-
body binding and centrifuged, and the cell pellet was re-
suspended in the antibody mixtures as described above and 
incubated for 20 min on ice (in the dark). Then, the cells 
were washed twice with PBS/0.5 % BSA and finally re-
suspended in 1 % paraformaldehyde (LUMC). The acquisi-
tion on the Fortessa (BD) was performed immediately after 
the staining was finished. Analysis was performed by using 
DIVA software (version 6.2). An example of the gating 
strategy for the memory and inhibitory panel is provided 
in Supplementary Fig. 1. Following the frequency analysis, 
the data were subjected to a Multi-experimental viewer 4 
(MeV4.0) software containing an algorithm for hierarchical 
clustering using Euclidean distance and complete linkage.
Results
HPV‑specific primary and secondary expansion 
of TDLN‑derived T cells
In a first attempt to expand HPV-specific T cells from 
TDLN, isolated LNMC of three patients (C394, C462 and 
C711, indicated by -I) were stimulated with antigen and 
cultured in the presence of different concentrations of IL-2 
(75, 150 or 300 U/ml) or TCGF/IL-15, the latter based on 
our successful homeostatic culture protocol for TIL [17]. 
Cytokines were provided at the start, medium refreshment 
and split of the cultures. The expansion with 150 and 300 
U/ml IL-2 was higher compared to 75 U/ml IL-2 or TCGF/
IL-15 (Supplementary Fig. 2). There were no overt differ-
ences in the percentage of HPV-specific T cells between the 
cultures (Supplementary Fig. 3). Since this concentration 
of IL-2 was also used in our GMP-compliant ACT proto-
col for the generation of melanoma-specific T cell batches 
[27], the subsequent expansions of HPV-specific T cells 
from patient TDLN were performed with 150 U/ml of IL-2. 
LNMC were cultured from minced TDLN (C331, C427, 
C711, C707, C726, C727) and scraped TDLN (C800, 
C809, C796). After 22 days of culture, the expansion varied 
between fourfold and 92-fold (mean 36; median 29; Sup-
plementary Fig. 4) and displayed exponential growth after 
6–8 days (data not shown). Repeat with LNMC of the three 
initial patients (C711, C726, C727; indicated by -II or -III) 
showed a comparable expansion. Notably, the yield of T 
cells after 22 days of culture was not associated with the 
initial starting number of LNMC.
To assess the peptide-specific secondary expansion 
capacity, the LNMC cultures of four patients (C331, 
C427, C707 and C711) obtained after the initial 22 days of 
stimulation were re-stimulated with HPV-specific E6 and 
E7 peptides loaded on autologous monocytes. All cultures 
expanded after this second stimulation, albeit that the fold 
expansion differed between patients and differed from the 
first expansion round (Fig. 1a). The strength of HPV-spe-
cific T cell proliferation (Fig. 1b) and cytokine production 
(Supplementary Fig. 5) was maintained after peptide-spe-
cific secondary expansion.
Cytokine profiles of peptide‑expanded HPV‑specific 
LNMC
The nine IL-2 expanded LNMC cultures and three repeated 
LNMC cultures (Supplementary Fig. 4) were analyzed for 
HPV specificity by their capacity to proliferate upon stimu-
lation with HPV16 E6 and E7 peptides. Overall, HPV pep-
tide-specific T cell proliferation was detected in the LNMC 
cultures of eight patients. HPV-specific IFNγ production 
was detected in all twelve tested cultures stimulated with 
peptide and in ten of the twelve LNMC cultures stimulated 
with protein (range 28 to >8000 pg/ml). In eleven cultures, 
also IL-10 and/or IL-5 was detected. Figure 2 shows three 
representative examples of HPV-specific proliferation and 
cytokine production. The cytokine profile varied from a 
predominant Th1 type (IFNγ and TNFα) to a mixed Th1/
Th2 type (IFNγ, IL-10 and IL-5). The results of the three 
repeated cultures showed HPV-specific IFNγ produc-
tion in two cases (Fig. 3). In the other case (C726-II), the 
LNMC were still too activated, indicated by the high level 
of IFNγ in the non-stimulated (unloaded) condition, but 
when analyzed by flow cytometry it did show HPV-specific 
reactivity. Thus, overall the stimulation procedure was 
reproducible.
Peptide‑expanded LNMC consist of polyclonal 
HPV‑specific CD4+ and CD8+ T cell populations
To analyze the type and fine specificity of T cells respond-
ing to HPV, a multiparameter flow cytometric analysis was 
performed on the nine LNMC cultures stimulated with 150 
U/ml of IL-2 cryopreserved at day 22. The percentage of 
CD4+ and CD8+ T cells expressing the activation mark-
ers CD137 (for CD4+ or CD8+ T cells) and/or CD154 
(for CD4+ T cells) after stimulation with HPV16 E6 and 
E7 peptide pools or protein was examined to type and enu-
merate the HPV-specific T cells within the LNMC cultures. 
In all LNMC cultures, a HPV16-specific CD4+ T cell 
response, associated with IFNγ production, was detected 
(Fig. 4a). In seven cases, peptide recognition was paral-
leled with reactivity against protein-pulsed APC. In three 
patients also, HPV16-specific CD8+ T cells were detected.
To study the breadth of the responding T cell population, 
the 22-day expanded LNMC cultures of six patients were 
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stimulated with single overlapping peptides of HPV16 E6 
and E7. In addition, two of the repeated LNMC cultures 
(C726-II and C727-II) were taken along. Overall, seven 
out of these eight LNMC cultures displayed HPV16 E6 
responses and five of them displayed HPV16 E7 reactiv-
ity (Fig. 4b). In five of the six patients, the CD4+ T cells 
responded to three or more different peptides. HPV-specific 
CD8+ T cell reactivity was detected in two patients. The 
reactivity in the repeated LNMC cultures was comparable, 
if not broader, to the primary expanded cultures of these 
patients (Fig. 4c). Thus, the culture procedures followed 
were robust and led to comparable results when repeated.
We had sufficient material of the TDLN of patient C331 
to confirm the breadth of the HPV-specific T cell response 























































































Fig. 1  Expanded LNMC can be re-stimulated and remain spe-
cific and functional. LNMC cultures were prepared, and at day 22, 
these cells were subjected to another round of stimulation for again 
3 weeks to determine whether the cells can be re-stimulated and do 
not express an exhausted phenotype. a The fold expansion of the first 
and second stimulation round is given as well as the proliferative 
response (mean plus standard deviation) as counts per minute (cpm; 
b), the latter being a measure for the incorporation of 3H-thymidine
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by using T cell clones. In total, six CD4+ and five CD8+ 
HPV-specific T cell clones were obtained (Supplementary 
Table 1) that proliferated and produced IFNγ after stimu-
lation with peptides. The result showed that the CD8+ T 
cells responded to E6 peptides 41 and 131/137, whereas 
CD4+ clones reacted to E6 peptides 91 or 101 as well as to 
E7 peptide 1 or 71 (Supplementary Table 1).
Expansion of HPV‑specific T cells from TDLN 
under full GMP conditions
To validate our method for clinical use, we completely 
repeated the protocol under full GMP conditions. TDLN 
of three patients (C726, C800 and C809) were stimu-
lated and analyzed. HPV reactivity was assessed by IFNγ 
ELISA because this assay is validated by the manufacturer 
and specific IFNγ secretion is a release criterium for clini-
cal T cell batches [27]. The expansion was 14- to 183-fold 
after 22 days of culture (Fig. 5a). In two patients (C726 
and C809), the expansion was much better than previ-
ously observed, whereas in one case (C800), it was lower. 
Importantly, the HPV16-specific proliferation and cytokine 
production (IFNγ/IL-10) were comparable between the T 
cell batches cultured under research or full GMP conditions 
(Fig. 5b).
HPV‑specific LNMC cultures display an effector 
memory phenotype
Further characterization of all fifteen obtained peptide-
stimulated LNMC cultures (both research and GMP), 
derived from cells initially expanded with 150 U/ml of 
IL-2, was performed by flow cytometry using an anti-
body panel for memory and inhibitory markers as well as 
to detect HPV-specific CD4+ CD25+ FoxP3+ regulatory 
T cells, for which we previously showed that they can be 
present in patients with HPV16-induced cancer [18, 28]. 
However, we did not find an overt expansion of CD25hi-
FoxP3+ T cells (mean 1.65 %, range 0.42–5.08 % at day 
22 compared with the results at the start of the culture; 
mean 1.26, range 0.21–2.30 %).
All LNMC cultures contained more than 90 % viable 
CD3+ T cells, and while between patients, the content 
of CD4+ and CD8+ T cells varied, this was not the case 
between repeated LNMC cultures of individual patients 
(Supplementary Fig. 6a). Due to the peptide stimulation 
in vitro, almost all cells were CD45RO+. The major-
ity displayed an effector memory phenotype, albeit that 
in some cases, small percentages of central memory stem 
cells (Tscm) could be detected. Also in a few cultures, 
CD8+ effector memory CD45RA+ cells (TEMRA) were 
observed. For the five cases in which one or more repeats 
of the LNMC stimulation procedure were performed 
(C711, C726, C727, C800 and C809), the repeats nicely 
clustered together per patient when hierarchical cluster-
ing was used (Supplementary Fig. 6b). The LNMC were 
























































































Fig. 2  Representative examples of the proliferation and cytokine pro-
duction of three LNMC cultures. The 22-day cultured LNMC were 
subjected to a 3-day proliferation assay to determine the response to 
HPV16 E6 and/or E7 22-mer peptides. Unloaded autologous mono-
cytes served as negative control. The proliferative response is given as 
the stimulation index (SI) when stimulated with peptide- or protein-
loaded autologous monocytes and is displayed on the left y-axis. The 
supernatant harvested after 48 h of stimulation was used for cytokine 
analysis by CBA, which is shown in the right y-axis
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TIM3 and CTLA-4. The majority of the CD4+ T cells 
expressed PD-1 often in combination with TIM3, whereas 
only a minority of the CD8+ T cells expressed PD-1 and/
or TIM3. CTLA-4 expression was hardly detected on T 
cells (Supplementary Fig. 7a). Although the expression of 
these markers varied between the LNMC cultures of differ-
ent patients, there were no overt differences in the repeated 
LNMC cultures from individual patients (Supplementary 
Fig. 7b). Altogether, the results show that the peptide-stim-
ulated LNMC cultures are of an activated effector mem-
ory T cell phenotype. There was no relation between the 
expression of the different markers analyzed and the fre-
quencies of HPV-specific T cells as determined by intracel-
lular cytokine staining (Fig. 4).
The potential use of PBMC as source for HPV‑specific 
T cells
The data of the directly ex vivo performed lymphocyte 
stimulation test (LST) with PBMCs of cervical cancer 
patients suggested that LNMC were more useful than 
PBMC as a source for HPV-specific T cells [16]. The LST 
is a proliferation assay in which freshly isolated PBMCs 
are stimulated with HPV peptides for a total of 7 days and 
proliferation is measured using 3H-thymidine. To validate 
this, we applied the HPV peptide stimulation protocol 
with 150 U/ml IL-2 as described above to blood samples, 
obtained before radical surgery, from eight HPV16+ cer-
vical cancer patients. We selected four patients displaying 
a HPV-specific proliferative response in PBMC (LST+), 
and as control four patients without such response (LST−). 
The fold expansion (Fig. 6a) and HPV specificity (Fig. 6b) 
were determined. In three of the four LST+ patients, the 
expanded PBMC displayed a secondary proliferative 
response when stimulated with HPV antigens. In addi-
tion, also in one of the PBMC cultures of LST− patients, 
a secondary HPV-specific proliferation was found. Subse-
quently, we measured the production of IFNγ and IL-10 
in the supernatant of these cultures. IFNγ was detected 
whenever the PBMCs displayed an HPV-specific prolif-
erative response. Unexpectedly, HPV-specific IFNγ pro-
duction was also detected in two of the PBMC cultures of 
LST− patients (C106 and C144) that did not show HPV-
specific proliferation. The results demonstrate that although 
PBMCs from HPV16+ cervical cancer patients can be 
used for enriching and expanding HPV16-specific T cells, 
based on the secondary proliferative capacity of the stimu-
lated PBMC, this will not be possible in all patients and the 
highest success rate will be obtained in those patients pre-
viously showing a positive LST response.
C711-I C726-I C727-I

















































Fig. 3  Complete repeat of LNMC cultures gives similar HPV16-
specific responses. From 3 patients, the LNMC cultures could be 
repeated with the cryopreserved TDLN cells. The production of IFNγ 
upon stimulation with peptide- or protein-loaded autologous mono-
cytes as measured by CBA is given. As a negative control, unloaded 
autologous monocytes are taken along. The results of both the first 
(-I) and second (-II) complete runs are displayed
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Discussion
In this explorative study, we found that isolation and expan-
sion of HPV16-specific LNMC derived from TDLN of 
patients with HPV16-induced cervical cancer are feasible 
and result in the generation of a polyclonal HPV-specific 
T cell response in all eleven tested patients. After stimu-
lation with GMP-grade E6 and E7 peptides and IL-2, the 
LNMC expanded ~36-fold. The expansion of HPV16-spe-
cific CD4+ T cell was found in all nine patients tested in 
detail, and in three patients, also HPV16-specific CD8+ T 
cells were detected. The bias toward CD4+ T cell reactiv-
ity against HPV-derived epitopes is not likely a result of 
the culture method used here, but more a reflection of what 
is generally found in the spontaneous T cell response to 
HPV in cervical cancer [17, 18, 29–31], as well as among 
TILs from patients with head and neck cancer [32]. The 
T helper type 1 (Th1) cytokine IFNγ was produced in all 
LNMC cultures and in some cases also the Th2 cytokines 
IL-10 and IL-5. Importantly, the procedure was reproduci-
ble as complete repeats of the stimulation procedures under 
research and under full GMP conditions showed similar 
results when compared to the first runs. Promising results 
already have been obtained in a pilot study in colorectal 
cancer patients, as immunotherapy or in adjuvant setting, 
using TDLN-expanded T cells for ACT [33, 34].
The HPV peptide-stimulated LNMC cultures predomi-
nantly contained HPV16-specific CD4+ T cells, producing 
IFNγ and/or IL-5. HPV16-specific T cells with this mixed 
cytokine profile were also found in antigen-experienced 
healthy individuals [35] and in patients with a complete 
regression of their HPV16-induced high-grade vulvar 
lesion after therapeutic vaccination [13, 14, 23], indicat-
ing that the responding LNMC cells acquired an appro-
priate cytokine profile during the stimulation procedure. 
The outgrowth of tumor-specific T cells of only a CD4+ 
phenotype should not pose a problem for their use in ACT. 
Although successes have been achieved with ACT prod-
ucts containing merely tumor-directed CD8+ T cells [36, 
37], there are indications that CD4+ T cells can help or 
can do the job. Substantial or complete tumor regressions 
have been achieved by ACT of T cells consisting only or 
mainly of CD4+ T cells [7, 38–40]. Transferred CD4+ T 
cells can contribute to antigen spreading [38], enhance the 
recruitment of CD8+ T cells to the tumor as well as sustain 
their effector function [41], reduce CD8+ T cell exhaus-
tion [42], switch tumor-induced M2 macrophages to acti-
vated M1-like macrophages [43] and kill tumor cells via 
direct and indirect mechanisms [44, 45]. Thus, the infusion 
of tumor-specific Th1 cells may have great clinical benefit 
by altering the tumor micromilieu into a preferred type 1 
cytokine-associated immune contexture [46].
In a number of ACT studies in metastatic melanoma, 
the tumor-specific T cells are derived from PBMC [27, 47, 
48]. Based on our previous study on HPV-specific T cell 
responses in almost 100 patients with cervical cancer, we 
predicted that the PBMC of patients with cervical cancer 
would be an inferior source for HPV16-specific T cells 
than TDLN. We stimulated the PBMCs of eight different 
HPV16+ cervical cancer patients and detected a second-
ary proliferative response with production of IFNγ in four 
patients, three of which was expected based on the earlier 
conducted LST. The stimulated and expanded PBMC of 
two additional patients produced only IFNγ when stimu-
lated with HPV16 antigens, suggesting that these cells lost 
their capacity of secondary peptide-specific expansion. 
These data suggest that PBMCs can be used as a source for 
successful expansion of HPV-specific T cells in about 50 % 
of the cases, and the highest success rate (100 %), however, 
is obtained when TDLN are used as source.
The relatively low numbers of obtained T cells after 
ex vivo expansion may be a limitation in ACT studies. 
Success rates of 50–70 % have been described in ACT 
studies in patients with metastatic melanoma [8, 37, 49]. 
In these studies, the functional properties, including the 
expansion rate and the presence of Th1 cytokines, and the 
total number of the transfused T cells were shown to cor-
relate with clinical success. Most melanoma patients in the 
first ACT studies received over 1011 cells. In this study, we 
were able to expand 1–5 × 106 LNMC to 36–180 × 106 
T cells per patient, respectively. It is not likely that the 
amount of starting material will be more in a clinical set-
ting. Lymph node material will have to be collected dur-
ing histological biopsy, and in our experience, on average 
12 × 106 (range 0–72 × 106; median 5.6 × 106; n = 48) 
LNMC are obtained when TDLN isolated during pelvic 
lymphadenectomy are scraped (unpublished data). There 
is evidence that ACT with lower numbers of T cells also 
results in clinical benefit. A recent study in melanoma 
patients showed that transfusions of on average 5 × 108 T 
Fig. 4  LNMC cultures harbor a broad HPV-specific T cell reper-
toire. The type and breadth of the HPV-specific T cell response in 
LNMC cultures were determined by intracellular cytokine stain-
ing in which both the activation and functionality of the T cells can 
be measured. LNMC were stimulated overnight with autologous 
monocytes loaded with peptide pools (a), single peptides or the cor-
responding whole protein (b) as indicated. The expression of the 
activation markers CD154 and CD137 were measured as well as the 
production of the cytokine IFNγ. Unloaded autologous monocytes 
are used as background staining. Depicted here is a heat map show-
ing the fold induction above background staining for both the CD4+ 
and CD8+ T cells. A fold induction of at least three is considered 
positive. The results of a complete repeat of LNMC culture for two 
patients are included. Notably, from C796, C800 and C809, no sin-
gle peptide analysis was performed. c Similar to b, the frequencies of 
the cytokine producing HPV-specific T cells are given for the LNMC 
cultures of the two patients that could be completely repeated. The 
results of both the first (-I) and second (-II) runs are given
◂
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cells lead to clinical responses in half of the patients [27]. 
Moreover, a single transfusion of 0.37–2.2 × 105 cyto-
megalovirus-specific CD8+ T cells/kg body weight after 
allogeneic stem cell transplantation leads to viral clearance 
in acute leukemia patients [50]. As the expanded num-
bers of LNMC using the current protocol will be lower 
than transferred to melanoma patients but the tumor anti-
gens are known, there is the option to increase the effects 
of ACT by vaccination following T cell transfer [46]. We 
recently showed that vaccination induced in vivo massive 
(<1000-fold) clonal expansions and regression of tumors 
in a mouse melanoma model [51]. Notably, in HPV-driven 
cancers, the tumor-specific antigens are always the same. 
Hence, the use of an off-the-shelf vaccine, such as the 
HPV16 synthetic long peptide vaccine with proven strong 
immunogenicity in end-stage cervical carcinoma patients 
[22, 26, 52, 53], following ACT may lead to massive num-
bers of HPV-specific polyclonal T cells in patients with 
HPV16-induced cancer.
Taken together, our results show that all TDLN cell cul-
tures isolated from patients with HPV16-induced cervical 
cancer are a rich source of polyclonal HPV-specific Th1 
and Th2 cells, which after proper ex vivo stimulation can 
be expanded under full GMP conditions. These HPV-spe-
cific T cells may be used in future ACT studies in patients 




























































































































































































































Fig. 5  LNMC cultures can be performed successfully under GMP 
conditions. From 3 patients, the LNMC cultures were initiated under 
research conditions or full GMP conditions at the GMP facility of 
the LUMC. a The fold expansion of under both research (white bars) 
and GMP conditions (black bars) is shown. b The proliferation (indi-
cated by stimulation index on left y-axis) and cytokine production by 
ELISA (indicated on right y-axis) in both LNMC cultures of the 3 
patients are shown
1461Cancer Immunol Immunother (2016) 65:1451–1463 
1 3
Acknowledgments The authors wish to thank Prof. Lex Peters, Dr. 
Katja Gaarenstroom and Dr. Cor de Kroon for collecting the lymph 
node samples. Dr. Jan Wouter Drijfhout and Dr. Willemien Benck-
huijsen and her colleagues are acknowledged for synthesis of the pep-
tides and Kees Franken for the recombinant protein preparation used 
for the immunological analyses. This study was financially supported 
by The Netherlands Organisation for Health Research and Develop-
ment (NWO ZonMw 916.96.085, to MIE van Poelgeest) and Dutch 
Cancer Society (Grant 2009-4400 to SH van der Burg).
Compliance with ethical standards 
Conflict of interest The authors declare that they have no conflict of 
interest.
Open Access This article is distributed under the terms of the Crea-
tive Commons Attribution 4.0 International License (http://crea-
tivecommons.org/licenses/by/4.0/), which permits unrestricted use, 
distribution, and reproduction in any medium, provided you give 
appropriate credit to the original author(s) and the source, provide a 
link to the Creative Commons license, and indicate if changes were 
made.
References
 1. Bruni L, Barrionuevo-Rosas L; Albero G, Aldea M, Serrano B, 
Valencia S, Brotons M, Mena M, Cosano R, Muñoz J, Bosch FX, 
de Sanjosé S, Castellsagué X (2016) Human papillomavirus and 
related diseases in the world. ICO Information Centre on HPV 
and Cancer (HPV Information Centre). Accessed 02 May 2016
 2. Bosch FX, de Sanjose S (2003) Chapter 1: human papillomavi-
rus and cervical cancer—burden and assessment of causality. J 
Natl Cancer Inst Monogr 31:3–13
 3. Pisani P, Bray F, Parkin DM (2002) Estimates of the world-wide 
prevalence of cancer for 25 sites in the adult population. Int J 
Cancer 97(1):72–81
 4. Larson DM, Copeland LJ, Stringer CA, Gershenson DM, 
Malone JM Jr, Edwards CL (1988) Recurrent cervical carcinoma 
after radical hysterectomy. Gynecol Oncol 30(3):381–387
 5. Burke TW, Hoskins WJ, Heller PB, Shen MC, Weiser EB, Park 
RC (1987) Clinical patterns of tumor recurrence after radical 
hysterectomy in stage IB cervical carcinoma. Obstet Gynecol 
69(3 Pt 1):382–385
 6. Zur Hausen H (1996) Papillomavirus infections—a major cause 
of human cancers. Biochim Biophys Acta 1288(2):F55–F78




















































































































































































































Fig. 6  HPV-specific bulk cultures can be obtained from PBMCs of 
HPV16+ cervical cancer patients. PBMCs of HPV16+ cervical can-
cer patients were cultured according to the LNMC culture protocol 
and after 3 weeks subjected to the proliferation assay and cytokine 
analysis. Four patients with a previously negative response as deter-
mined by the lymphocyte stimulation test (LST−) and 4 patients with 
a positive reactivity (LST+) were selected for this purpose. a The 
fold expansion of the PBMC cultures are depicted. b The prolifera-
tive response (indicated by stimulation index (SI) on the left y-axis) 
and cytokine production as determined by ELISA (indicated on right 
y-axis) are given. The dotted line indicates a SI of 3, which is defined 
as the threshold for a positive proliferative response
1462 Cancer Immunol Immunother (2016) 65:1451–1463
1 3
 7. Verdegaal EM (2016) Adoptive cell therapy: a highly success-
ful individualized therapy for melanoma with great poten-
tial for other malignancies. Curr Opin Immunol 39:90–95. 
doi:10.1016/j.coi.2016.01.004
 8. Rosenberg SA, Yang JC, Sherry RM, Kammula US, Hughes MS, 
Phan GQ, Citrin DE, Restifo NP, Robbins PF, Wunderlich JR, 
Morton KE, Laurencot CM, Steinberg SM, White DE, Dudley 
ME (2011) Durable complete responses in heavily pretreated 
patients with metastatic melanoma using T-cell transfer immuno-
therapy. Clin Cancer Res 17(13):4550–4557. doi:10.1158/1078-
0432.CCR-11-0116
 9. Dudley ME, Yang JC, Sherry R, Hughes MS, Royal R, Kam-
mula U, Robbins PF, Huang J, Citrin DE, Leitman SF, Wunder-
lich J, Restifo NP, Thomasian A, Downey SG, Smith FO, Klap-
per J, Morton K, Laurencot C, White DE, Rosenberg SA (2008) 
Adoptive cell therapy for patients with metastatic melanoma: 
evaluation of intensive myeloablative chemoradiation prepara-
tive regimens. J Clin Oncol 26(32):5233–5239. doi:10.1200/
JCO.2008.16.5449
 10. Linnemann C, van Buuren MM, Bies L, Verdegaal EM, Schotte 
R, Calis JJ, Behjati S, Velds A, Hilkmann H, Atmioui DE, Visser 
M, Stratton MR, Haanen JB, Spits H, van der Burg SH, Schu-
macher TN (2015) High-throughput epitope discovery reveals 
frequent recognition of neo-antigens by CD4+ T cells in human 
melanoma. Nat Med 21(1):81–85. doi:10.1038/nm.3773
 11. Lu YC, Yao X, Crystal JS, Li YF, El-Gamil M, Gross C, Davis 
L, Dudley ME, Yang JC, Samuels Y, Rosenberg SA, Robbins PF 
(2014) Efficient identification of mutated cancer antigens rec-
ognized by T cells associated with durable tumor regressions. 
Clin Cancer Res 20(13):3401–3410. doi:10.1158/1078-0432.
CCR-14-0433
 12. van der Burg SH, Melief CJ (2011) Therapeutic vaccination 
against human papilloma virus induced malignancies. Curr Opin 
Immunol 23(2):252–257. doi:10.1016/j.coi.2010.12.010
 13. Kenter GG, Welters MJ, Valentijn AR, Lowik MJ, Berends-van 
der Meer DM, Vloon AP, Essahsah F, Fathers LM, Offringa R, 
Drijfhout JW, Wafelman AR, Oostendorp J, Fleuren GJ, van 
der Burg SH, Melief CJ (2009) Vaccination against HPV-16 
oncoproteins for vulvar intraepithelial neoplasia. N Engl J Med 
361(19):1838–1847. doi:10.1056/NEJMoa0810097
 14. van Poelgeest MI, Welters MJ, Vermeij R, Stynenbosch LF, Loof 
NM, Berends-van der Meer DM, Lowik MJ, Hamming IL, van 
Esch EM, Hellebrekers BW, van Beurden M, Schreuder HW, 
Kagie MJ, Trimbos JB, Fathers L, Daemen T, Hollema H, Val-
entijn R, Oostendorp J, Oude Elberink JH, Fleuren GJ, Bosse 
T, Kenter GG, Stijnen T, Nijman HW, Melief CJ, van der Burg 
SH (2016) Vaccination against oncoproteins of HPV16 for non-
invasive vulvar/vaginal lesions: lesion clearance is related to the 
strength of the T-cell response. Clin Cancer Res 22(10):2342–
2350. doi:10.1158/1078-0432.CCR-15-2594
 15. Stevanovic S, Draper LM, Langhan MM, Campbell TE, Kwong 
ML, Wunderlich JR, Dudley ME, Yang JC, Sherry RM, Kam-
mula US, Restifo NP, Rosenberg SA, Hinrichs CS (2015) Com-
plete regression of metastatic cervical cancer after treatment with 
human papillomavirus-targeted tumor-infiltrating T cells. J Clin 
Oncol 33(14):1543–1550. doi:10.1200/JCO.2014.58.9093
 16. Heusinkveld M, Welters MJ, van Poelgeest MI, van der Hulst 
JM, Melief CJ, Fleuren GJ, Kenter GG, van der Burg SH (2011) 
The detection of circulating human papillomavirus-specific T 
cells is associated with improved survival of patients with deeply 
infiltrating tumors. Int J Cancer 128(2):379–389. doi:10.1002/
ijc.25361
 17. Piersma SJ, Welters MJ, van der Hulst JM, Kloth JN, Kwap-
penberg KM, Trimbos BJ, Melief CJ, Hellebrekers BW, Fleuren 
GJ, Kenter GG, Offringa R, van der Burg SH (2008) Human 
papilloma virus specific T cells infiltrating cervical cancer and 
draining lymph nodes show remarkably frequent use of HLA-
DQ and -DP as a restriction element. Int J Cancer 122(3):486–
494. doi:10.102/ijc.23162
 18. de Vos van Steenwijk PJ, Heusinkveld M, Ramwadhdoebe 
TH, Lowik MJ, van der Hulst JM, Goedemans R, Piersma SJ, 
Kenter GG, van der Burg SH (2010) An unexpectedly large poly-
clonal repertoire of HPV-specific T cells is poised for action in 
patients with cervical cancer. Cancer Res 70(7):2707–2717. 
doi:10.1158/0008-5472.CAN-09-4299
 19. Claas EC, Melchers WJ, van der Linden HC, Lindeman J, Quint 
WG (1989) Human papillomavirus detection in paraffin-embed-
ded cervical carcinomas and metastases of the carcinomas by the 
polymerase chain reaction. Am J Pathol 135(4):703–709
 20. Wherry EJ (2011) T cell exhaustion. Nat Immunol 
12(6):492–499
 21. Kim PS, Ahmed R (2010) Features of responding T cells in can-
cer and chronic infection. Curr Opin Immunol 22(2):223–230. 
doi:10.1016/j.coi.2010.02.005
 22. Welters MJ, Kenter GG, Piersma SJ, Vloon AP, Lowik MJ, Ber-
ends-van der Meer DM, Drijfhout JW, Valentijn AR, Wafelman 
AR, Oostendorp J, Fleuren GJ, Offringa R, Melief CJ, van der 
Burg SH (2008) Induction of tumor-specific CD4+ and CD8+ 
T-cell immunity in cervical cancer patients by a human papillo-
mavirus type 16 E6 and E7 long peptides vaccine. Clin Cancer 
Res 14(1):178–187. doi:10.1158/1078-0432.CCR-07-1880
 23. Welters MJ, Kenter GG, de Vos van Steenwijk PJ, Lowik MJ, Ber-
ends-van der Meer DM, Essahsah F, Stynenbosch LF, Vloon AP, 
Ramwadhdoebe TH, Piersma SJ, van der Hulst JM, Valentijn AR, 
Fathers LM, Drijfhout JW, Franken KL, Oostendorp J, Fleuren GJ, 
Melief CJ, van der Burg SH (2010) Success or failure of vaccina-
tion for HPV16-positive vulvar lesions correlates with kinetics and 
phenotype of induced T-cell responses. Proc Natl Acad Sci USA 
107(26):11895–11899. doi:10.1073/pnas.1006500107
 24. van der Burg SH, Ressing ME, Kwappenberg KM, de Jong A, 
Straathof K, de Jong J, Geluk A, van Meijgaarden KE, Franken 
KL, Ottenhoff TH, Fleuren GJ, Kenter G, Melief CJ, Offringa 
R (2001) Natural T-helper immunity against human papilloma-
virus type 16 (HPV16) E7-derived peptide epitopes in patients 
with HPV16-positive cervical lesions: identification of 3 human 
leukocyte antigen class II- restricted epitopes. Int J Cancer 
91(5):612–618
 25. Restifo NP, Dudley ME, Rosenberg SA (2012) Adoptive immu-
notherapy for cancer: harnessing the T cell response. Nat Rev 
Immunol 12(4):269–281. doi:10.1038/nri3191
 26. Welters MJ, van der Sluis TC, van Meir H, Loof NM, van Ham 
VJ, van Duikeren S, Santegoets SJ, Arens R, de Kam ML, 
Cohen AF, van Poelgeest MI, Kenter GG, Kroep JR, Burggraaf 
J, Melief CJ, van der Burg SH (2016) Vaccination during mye-
loid cell depletion by cancer chemotherapy fosters robust T cell 
responses. Sci Transl Med 8(334):334ra352. doi:10.1126/sci-
translmed.aad8307
 27. Verdegaal EM, Visser M, Ramwadhdoebe TH, van der Minne 
CE, van Steijn JA, Kapiteijn E, Haanen JB, van der Burg SH, 
Nortier JW, Osanto S (2011) Successful treatment of meta-
static melanoma by adoptive transfer of blood-derived poly-
clonal tumor-specific CD4+ and CD8+ T cells in combination 
with low-dose interferon-alpha. Cancer Immunol Immunother 
60(7):953–963. doi:10.1007/s00262-011-1004-8
 28. van der Burg SH, Piersma SJ, de Jong A, van der Hulst JM, 
Kwappenberg KM, van den Hende M, Welters MJ, Van Rood JJ, 
Fleuren GJ, Melief CJ, Kenter GG, Offringa R (2007) Associa-
tion of cervical cancer with the presence of CD4+ regulatory T 
cells specific for human papillomavirus antigens. Proc Natl Acad 
Sci USA 104(29):12087–12092. doi:10.1073/pnas.0704672104
 29. Pieterse QD, Kenter GG, Gaarenstroom KN, Peters AA, Wil-
lems SM, Fleuren GJ, Trimbos JB (2007) The number of pelvic 
1463Cancer Immunol Immunother (2016) 65:1451–1463 
1 3
lymph nodes in the quality control and prognosis of radical hys-
terectomy for the treatment of cervical cancer. Eur J Surg Oncol 
33(2):216–221. doi:10.1016/j.esjo.2006.09.039
 30. Evans M, Borysiewicz LK, Evans AS, Rowe M, Jones M, Gile-
adi U, Cerundolo V, Man S (2001) Antigen processing defects in 
cervical carcinomas limit the presentation of a CTL epitope from 
human papillomavirus 16 E6. J Immunol 167(9):5420–5428
 31. Seresini S, Origoni M, Caputo L, Lillo F, Longhi R, Vantini S, 
Paganoni AM, Protti MP (2010) CD4+ T cells against human 
papillomavirus-18 E7 in patients with high-grade cervical lesions 
associate with the absence of the virus in the cervix. Immunol-
ogy 131(1):89–98. doi:10.1111/j.1365-2567.2010.03277.x
 32. Ramos CA, Narala N, Vyas GM, Leen AM, Gerdemann U, Stur-
gis EM, Anderson ML, Savoldo B, Heslop HE, Brenner MK, 
Rooney CM (2013) Human papillomavirus type 16 E6/E7-spe-
cific cytotoxic T lymphocytes for adoptive immunotherapy 
of HPV-associated malignancies. J Immunother 36(1):66–76. 
doi:10.1097/CJI.0b013e318279652e
 33. Zhen YH, Liu XH, Yang Y, Li B, Tang JL, Zeng QX, Hu J, Zeng 
XN, Zhang L, Wang ZJ, Li XY, Ge HX, Winqvist O, Hu PS, Xiu 
J (2015) Phase I/II study of adjuvant immunotherapy with senti-
nel lymph node T lymphocytes in patients with colorectal can-
cer. Cancer Immunol Immunother Cancer Immunol Immunother 
64(9):1083–1093. doi:10.1007/s00262-015-1715-3
 34. Karlsson M, Marits P, Dahl K, Dagoo T, Enerback S, Thorn M, 
Winqvist O (2010) Pilot study of sentinel-node-based adoptive 
immunotherapy in advanced colorectal cancer. Ann Surg Oncol 
17(7):1747–1757. doi:10.1245/s10434-010-0920-8
 35. de Jong A, van Poelgeest MI, van der Hulst JM, Drijfhout JW, 
Fleuren GJ, Melief CJ, Kenter G, Offringa R, van der Burg SH 
(2004) Human papillomavirus type 16-positive cervical can-
cer is associated with impaired CD4+ T-cell immunity against 
early antigens E2 and E6. Cancer Res 64(15):5449–5455. 
doi:10.1158/0008.5472.CAN-04-0831
 36. Andersen R, Donia M, Ellebaek E, Borch TH, Kongsted 
P, Iversen TZ, Hölmich LR, Hendel HW, Met Ö, Andersen 
MH, Thor Straten P, Svane IM (2016) Long-lasting complete 
responses in patients with metastatic melanoma after adop-
tive cell therapy with tumor-infiltrating lymphocytes and an 
attenuated IL2 regimen. Clin Cancer Res 22(15):3734–3745. 
doi:10.1158/1078-0432.CCR-15-1879
 37. Rosenberg SA, Dudley ME (2009) Adoptive cell therapy for 
the treatment of patients with metastatic melanoma. Curr Opin 
Immunol 21(2):233–240. doi:10.1016/j.coi.2009.03.002
 38. Hunder NN, Wallen H, Cao J, Hendricks DW, Reilly JZ, Rod-
myre R, Jungbluth A, Gnjatic S, Thompson JA, Yee C (2008) 
Treatment of metastatic melanoma with autologous CD4+ T 
cells against NY-ESO-1. N Engl J Med 358(25):2698–2703. 
doi:10.1056/NEJMoa0800251
 39. Tran E, Turcotte S, Gros A, Robbins PF, Lu YC, Dudley ME, 
Wunderlich JR, Somerville RP, Hogan K, Hinrichs CS, Parkhurst 
MR, Yang JC, Rosenberg SA (2014) Cancer immunotherapy 
based on mutation-specific CD4+ T cells in a patient with 
epithelial cancer. Science 344(6184):641–645. doi:10.1126/
science.1251102
 40. Leen AM, Christin A, Myers GD, Liu H, Cruz CR, Hanley PJ, 
Kennedy-Nasser AA, Leung KS, Gee AP, Krance RA, Brenner 
MK, Heslop HE, Rooney CM, Bollard CM (2009) Cytotoxic 
T lymphocyte therapy with donor T cells prevents and treats 
adenovirus and Epstein-Barr virus infections after haploiden-
tical and matched unrelated stem cell transplantation. Blood 
114(19):4283–4292. doi:10.1182/blood-2009-07-232454
 41. Bos R, Sherman LA (2010) CD4+ T-cell help in the tumor 
milieu is required for recruitment and cytolytic function 
of CD8+ T lymphocytes. Cancer Res 70(21):8368–8377. 
doi:10.1158/0008-5472.CAN-10-1322
 42. Church SE, Jensen SM, Antony PA, Restifo NP, Fox BA (2014) 
Tumor-specific CD4+ T cells maintain effector and memory 
tumor-specific CD8+ T cells. Eur J Immunol 44(1):69–79. 
doi:10.1002/eji.201343718
 43. Heusinkveld M, de Vos van Steenwijk PJ, Goedemans R, Ram-
wadhdoebe TH, Gorter A, Welters MJ, van Hall T, van der Burg 
SH (2011) M2 macrophages induced by prostaglandin E2 and 
IL-6 from cervical carcinoma are switched to activated M1 mac-
rophages by CD4+ Th1 cells. J Immunol 187(3):1157–1165. 
doi:10.4049/jimmunol.1100889
 44. Hung K, Hayashi R, Lafond-Walker A, Lowenstein C, Pardoll D, 
Levitsky H (1998) The central role of CD4(+) T cells in the anti-
tumor immune response. J Exp Med 188(12):2357–2368
 45. Quezada SA, Simpson TR, Peggs KS, Merghoub T, Vider J, Fan X, 
Blasberg R, Yagita H, Muranski P, Antony PA, Restifo NP, Allison 
JP (2010) Tumor-reactive CD4(+) T cells develop cytotoxic activity 
and eradicate large established melanoma after transfer into lympho-
penic hosts. J Exp Med 207(3):637–650. doi:10.1084/jem.20091918
 46. van der Burg SH, Arens R, Ossendorp F, van Hall T, Melief CJ 
(2016) Vaccines for established cancer: overcoming the chal-
lenges posed by immune evasion. Nat Rev Cancer 16(4):219–
233. doi:10.1038/nrc.2016.16
 47. Bouquie R, Bonnin A, Bernardeau K, Khammari A, Dreno B, 
Jotereau F, Labarriere N, Lang F (2009) A fast and efficient HLA 
multimer-based sorting procedure that induces little apoptosis 
to isolate clinical grade human tumor specific T lymphocytes. 
Cancer Immunol Immunother 58(4):553–566. doi:10.1007/
s00262-008-0578-2
 48. Hinrichs CS, Spolski R, Paulos CM, Gattinoni L, Kerstann KW, 
Palmer DC, Klebanoff CA, Rosenberg SA, Leonard WJ, Res-
tifo NP (2008) IL-2 and IL-21 confer opposing differentiation 
programs to CD8+ T cells for adoptive immunotherapy. Blood 
111(11):5326–5333. doi:10.1182/blood-2007-09-113050
 49. Rosenberg SA, Restifo NP, Yang JC, Morgan RA, Dudley ME (2008) 
Adoptive cell transfer: a clinical path to effective cancer immunother-
apy. Nat Rev Cancer 8(4):299–308. doi:10.1038/nrc2355
 50. Schmitt A, Tonn T, Busch DH, Grigoleit GU, Einsele H, Oden-
dahl M, Germeroth L, Ringhoffer M, Ringhoffer S, Wiesneth 
M, Greiner J, Michel D, Mertens T, Rojewski M, Marx M, 
von Harsdorf S, Dohner H, Seifried E, Bunjes D, Schmitt 
M (2011) Adoptive transfer and selective reconstitution of 
streptamer-selected cytomegalovirus-specific CD8+ T cells 
leads to virus clearance in patients after allogeneic peripheral 
blood stem cell transplantation. Transfusion 51(3):591–599. 
doi:10.1111/j.1537-2995.2010.02940.x
 51. Ly LV, Sluijter M, Versluis M, Luyten GP, van Stipdonk MJ, van 
der Burg SH, Melief CJ, Jager MJ, van Hall T (2010) Peptide 
vaccination after T-cell transfer causes massive clonal expansion, 
tumor eradication, and manageable cytokine storm. Cancer Res 
70(21):8339–8346. doi:10.1158/0008-5472.CAN-10-2288
 52. Kenter GG, Welters MJ, Valentijn AR, Lowik MJ, Berends-van 
der Meer DM, Vloon AP, Drijfhout JW, Wafelman AR, Oost-
endorp J, Fleuren GJ, Offringa R, van der Burg SH, Melief CJ 
(2008) Phase I immunotherapeutic trial with long peptides span-
ning the E6 and E7 sequences of high-risk human papillomavi-
rus 16 in end-stage cervical cancer patients shows low toxicity 
and robust immunogenicity. Clin Cancer Res 14(1):169–177. 
doi:10.1158/1078-0432.CCR-07-1881
 53. van Poelgeest MI, Welters MJ, van Esch EM, Stynenbosch LF, 
Kerpershoek G, van Persijn van Meerten EL, van den Hende 
M, Lowik MJ, Berends-van der Meer DM, Fathers LM, Valen-
tijn AR, Oostendorp J, Fleuren GJ, Melief CJ, Kenter GG, van 
der Burg SH (2013) HPV16 synthetic long peptide (HPV16-
SLP) vaccination therapy of patients with advanced or recur-
rent HPV16-induced gynecological carcinoma, a phase II trial. J 
Transl Med 11:88. doi:10.1186/1479-5876-11-88
